AAAAAA

   
Results: 1-8 |
Results: 8
PHARMACEUTICAL DEVELOPMENT OF A PARENTERAL LYOPHILIZED FORMULATION OFTHE INVESTIGATIONAL ANTITUMOR NEUROPEPTIDE ANTAGONIST [ARG(6), D-TRP(7,9), MEPHE(8)]-SUBSTANCE P (6-11)
Authors: JONKMANDEVRIES JD ROSING H TALSMA H HENRAR REC KETTENESVANDENBOSCH JJ BULT A BEIJNEN JH
Citation: Jd. Jonkmandevries et al., PHARMACEUTICAL DEVELOPMENT OF A PARENTERAL LYOPHILIZED FORMULATION OFTHE INVESTIGATIONAL ANTITUMOR NEUROPEPTIDE ANTAGONIST [ARG(6), D-TRP(7,9), MEPHE(8)]-SUBSTANCE P (6-11), Investigational new drugs, 16(2), 1998, pp. 99-111
MANUFACTURING OF A LYOPHILIZED PARENTERAL DOSAGE FORM OF THE INDOLOQUINONE ANTITUMOR AGENT EO9 FOR PHASE-II CLINICAL-STUDIES IN THE SETTINGOF A HOSPITAL PHARMACY
Authors: JONKMANDEVRIES JD HENRAR REC BULT A BEIJNEN JH
Citation: Jd. Jonkmandevries et al., MANUFACTURING OF A LYOPHILIZED PARENTERAL DOSAGE FORM OF THE INDOLOQUINONE ANTITUMOR AGENT EO9 FOR PHASE-II CLINICAL-STUDIES IN THE SETTINGOF A HOSPITAL PHARMACY, Drug development and industrial pharmacy, 23(2), 1997, pp. 137-144
PHARMACEUTICAL DEVELOPMENT OF (INVESTIGATIONAL) ANTICANCER AGENTS FORPARENTERAL USE - A REVIEW
Authors: JONKMANDEVRIES JD FLORA KP BULT A BEIJNEN JH
Citation: Jd. Jonkmandevries et al., PHARMACEUTICAL DEVELOPMENT OF (INVESTIGATIONAL) ANTICANCER AGENTS FORPARENTERAL USE - A REVIEW, Drug development and industrial pharmacy, 22(6), 1996, pp. 475-494
PURITY DETERMINATIONS IN THE BULK DRUG OF THE NOVEL INDOLOQUINONE ANTITUMOR AGENT EO9
Authors: JONKMANDEVRIES JD KETTENESVANDENBOSCH JJ HENRAR REC BULT A BEIJNEN JH
Citation: Jd. Jonkmandevries et al., PURITY DETERMINATIONS IN THE BULK DRUG OF THE NOVEL INDOLOQUINONE ANTITUMOR AGENT EO9, Investigational new drugs, 14(2), 1996, pp. 181-191
SYSTEMATIC STUDY ON THE CHEMICAL-STABILITY OF THE PRODRUG ANTITUMOR AGENT CARZELESIN (U-80,244)
Authors: JONKMANDEVRIES JD DOPPENBERG WG HENRAR REC BULT A BEIJNEN JH
Citation: Jd. Jonkmandevries et al., SYSTEMATIC STUDY ON THE CHEMICAL-STABILITY OF THE PRODRUG ANTITUMOR AGENT CARZELESIN (U-80,244), Journal of pharmaceutical sciences, 85(11), 1996, pp. 1227-1233
PHARMACOKINETICS OF ETOPOSIDE AFTER ORAL AND INTRAVENOUS ADMINISTRATION IN PATIENTS WITH GASTRIC-CARCINOMA
Authors: JONKMANDEVRIES JD ROSING H VANTELLINGEN O NEEF C DUBBELMAN AC BULT A TENBOKKELHUININK WW TAAL BG BEIJNEN JH
Citation: Jd. Jonkmandevries et al., PHARMACOKINETICS OF ETOPOSIDE AFTER ORAL AND INTRAVENOUS ADMINISTRATION IN PATIENTS WITH GASTRIC-CARCINOMA, Clinical drug investigation, 10(2), 1995, pp. 86-95
PHARMACEUTICAL DEVELOPMENT OF A PARENTERAL LYOPHILIZED FORMULATION OFTHE NOVEL INDOLOQUINONE ANTITUMOR AGENT E09
Authors: JONKMANDEVRIES JD TALSMA H HENRAR REC KETTENESVANDENBOSCH JJ BULT A BEIJNEN JH
Citation: Jd. Jonkmandevries et al., PHARMACEUTICAL DEVELOPMENT OF A PARENTERAL LYOPHILIZED FORMULATION OFTHE NOVEL INDOLOQUINONE ANTITUMOR AGENT E09, Cancer chemotherapy and pharmacology, 34(5), 1994, pp. 416-422
PHARMACEUTICAL DEVELOPMENT OF A PARENTERAL FORMULATION OF THE NOVEL ANTITUMOR AGENT CARZELESIN (U-80,244)
Authors: JONKMANDEVRIES JD DEGRAAFFTEULEN MJA HENRAR REC DENBOSCH JJKV BULT A BEIJNEN JH
Citation: Jd. Jonkmandevries et al., PHARMACEUTICAL DEVELOPMENT OF A PARENTERAL FORMULATION OF THE NOVEL ANTITUMOR AGENT CARZELESIN (U-80,244), Investigational new drugs, 12(4), 1994, pp. 303-314
Risultati: 1-8 |